SINTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sintx Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.70−0.04 (-2.30%)
Close on Oct 19, 2026
- Market cap
- $8.24M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
45.3%+25.3 pts over 5 years
Operating margin
-1053.1%+378.5 pts over 5 years
Net margin
-1018.1%+165.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -64.7% | -13.3% | +11.4% | -25.5% | |
| Gross profit | -77.8% | -29.1% | +31.1% | -28.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -115.5% | -45.3% | -303.8% | |
| Return on assets | -47.5% | -35.5% | -109.6% | |
| Current ratio | 1.14 | 9.58 | 1.51 | |
| Debt to equity | 1.68 | 0.02 | – | |
| Inventory turnover | 0.5× | 0.8× | 0.8× | |
| Capex to revenue | 4.4% | 60.6% | 18.2% | |
| Diluted shares | 0M | 0M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sintx Technologies generated $51.72M from operations and spent $6.69M on capital expenditure, dividends and share buybacks. 98% of that went back into the business.
Generated
$51.72M
Used
$6.69M
Capital expenditure$6.55M98%Dividends$00%Share buybacks$133.00K2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1018.1%
×Asset turnover0.11×
×Equity multiplier2.77×
=Return on equity, FY2025-303.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1018.1% | 0.11× | 2.77× | -303.8% |
| FY2024 | -381.8% | 0.23× | 1.96× | -174.1% |
| FY2023 | -314.4% | 0.17× | 2.15× | -114.1% |
| FY2022 | -771.2% | 0.08× | 1.64× | -105.1% |
| FY2021 | -1536.1% | 0.02× | 1.22× | -43.3% |
| FY2020 | -1183.3% | 0.03× | 1.28× | -45.3% |
| FY2019 | -696.2% | 0.07× | 1.52× | -70.5% |
| FY2018 | -9107.4% | 0.01× | 1.89× | -125.0% |
| FY2017 | -83.1% | 0.55× | 2.45× | -111.9% |
| FY2016 | -97.0% | 0.49× | 2.43× | -115.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$10.36M
- Cash generatingOperating cash flow above zero-$8.57M
- Return on assets improvedROA up on the prior year-71.7% → -110.1%
- Earnings backed by cashOperating cash flow above net income-$8.57M vs -$10.36M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.28 → 1.51
- No dilutionShare count did not rise1M → 3M
- Gross margin improvedGross margin up on the prior year71.91% → 45.28%
- More efficientAsset turnover rose0.19 → 0.11